<DOC>
	<DOCNO>NCT00938652</DOCNO>
	<brief_summary>The goal study determine effect overall survival progression free survival add iniparib ( BSI-201/SAR240550 ) combination gemcitabine/carboplatin adult patient triple negative breast cancer ( estrogen receptor ( ER ) -negative , progesterone receptor ( PR ) -negative , human epidermal growth factor receptor 2 ( HER2 ) -negative ) . Based data generate BiPar/Sanofi , conclude iniparib posse characteristic typical poly ( ADP-ribose ) polymerase ( PARP ) inhibitor class . The exact mechanism yet fully elucidate , however base experiment tumor cell perform laboratory , iniparib novel investigational anti-cancer agent induces gamma-H2AX ( marker DNA damage ) tumor cell line , induces cell cycle arrest G2/M phase tumor cell line , potentiates cell cycle effect DNA damage modality tumor cell line . Investigations potential target iniparib metabolite ongoing .</brief_summary>
	<brief_title>A Phase 3 , Multi-Center Study Gemcitabine/Carboplatin , With Without BSI-201 , Patients With ER- , PR- , Her2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>Participants treat 21-day cycle disease progression , unacceptable toxicity , consent withdrawal . After treatment discontinuation , participant follow end study death receipt new anticancer therapy , whichever first .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Iniparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically document breast cancer ( either primary metastatic site ) ERnegative , PRnegative , HER2 nonoverexpressing immunohistochemistry ( 0 , 1 ) fluorescence situ hybridization ( FISH ) . Triplenegative tumor define follow criterion : HER2nonoverexpressing : FISHnegative ( define ratio &lt; 2.2 ) , immunohistochemical ( IHC ) 0 , IHC 1+ , IHC 2+ IHC 3+ FISHnegative . ER PRnegative : &lt; 10 % tumor stain immunohistochemistry ( IHC ) . Never receive chemotherapy metastatic disease , receive 1 2 prior chemotherapy regimen metastatic setting ( Prior adjuvant/neoadjuvant therapy allow ) ; Metastatic breast cancer ( Stage IV ) measurable disease RECIST 1.1 criterion ; Female , ≥18 year age ; Eastern Cooperative Oncology Group ( ECOG ) performance status 01 ; Organ marrow function follow : absolute neutrophil count ( ANC ) ≥1500/mm3 , platelet ≥100,000/dL , hemoglobin ≥9 g/dL , bilirubin ≤1.5 mg/dL , serum creatinine ≤1.5 mg/dL creatinine clearance ≥60 mL/min , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.5 time upper limit normal liver involvement ≤5 time upper limit normal liver involvement ; Radiation therapy complete least 14 day study dose day 1 ; radiate lesion may serve measurable disease ; Central nervous system metastases allow subject require steroid , whole brain radiation therapy ( XRT ) , gamma/cyber knife , brain metastasis clinically stable without symptomatic progression ; For woman child bear potential , documented negative pregnancy test within two week study entry agreement acceptable birth control duration study therapy ; Tissue block ( primary metastatic ) readily available fresh frozen tumor tissue PARP expression pharmacogenomic study recommend ( although absence exclude subject participate ) ; No diagnosis malignancy ( exception non melanoma skin cancer malignancy diagnose ≥5 year ago ) ; Obtained informed consent ; Capability understand comply protocol sign informed consent document . Systemic anticancer therapy within 14 day first dose study drug ; Prior treatment gemcitabine , carboplatin , cisplatin iniparib Had recover grade ≤1 adverse event ( AEs ) per National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) v3.0 within 10 % baseline value due investigational drug medication administer 30 day prior study enrollment ; Major medical condition might affect study participation ( e.g . uncontrolled pulmonary , renal , hepatic dysfunction , uncontrolled infection , cardiac disease ) ; Concurrent radiation therapy intend treat primary tumor permit throughout course study ; palliative radiation acceptable ; Leptomeningeal disease brain metastasis require steroid therapeutic intervention ; Pregnancy breastfeeding ; Inability unwillingness abide study protocol cooperate fully investigator designee .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>triple negative breast cancer</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>Triple negative metastatic breast cancer</keyword>
</DOC>